A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada

Abstract

Cardiometabolic disease (CMD) is associated with an increased risk of metabolic dysfunction-associated steatohepatitis (MASH). Most patients develop MASH in association with type 2 diabetes and obesity. Optimal disease management requires effective multidisciplinary collaboration between primary care physicians and specialists from different medical fields; however, awareness of the risks, association with CMD, diagnosis, complications, and management strategies of MASH is low among non-liver specialists. In Canada, variable access to diagnostic testing and, until recently, the lack of national MASH guidelines, are also barriers to effective disease management. Ongoing cross-disciplinary education and wide systemic changes are required to ensure timely patient identification and the establishment of holistic patient care pathways that can begin to address MASH and associated CMD.